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Abstract
Arylpiperazine-based dopaminergic/serotonergic ligands exert
neuroprotectiveactivity.Weexamined theeffectofarylpiperazine
D2/5-HT1A ligands, N-{4-[2-(4-phenyl-piperazin-1-yl)-ethyl}-phe-
nyl]-picolinamide (6a) and N-{3-[2-(4-phenyl-piperazin-1-yl)-
ethyl]-phenyl}-picolinamide (6b), in experimental autoimmune
encephalomyelitis (EAE), a model of neuroinflammation. Both
compounds (10 mg/kg i.p.) reduced EAE clinical signs in spinal
cord homogenate-immunized Dark Agouti rats. Compound 6b
wasmoreefficient in delaying the disease onset and reducing the
maximal clinical score, which correlated with its higher affinity for
D2and5-HT1A receptors.Theprotectionwas retained if treatment
was limited to the effector (from day 8 onwards), but not the
induction phase (day 0–7) of EAE. Compound 6b reduced CNS
immune infiltration and expression of mRNA encoding the
proinflammatory cytokines tumor necrosis factor, IL-6, IL-1, and
GM-CSF, TH1 cytokine IFN-c, TH17 cytokine IL-17, aswell as the
signature transcription factors of TH1 (T-bet) and TH17 (RORct)
cells. Arylpiperazine treatment reduced apoptosis and increased
theactivationof anti-apoptoticmediatorsAkt andp70S6kinase in
the CNS of EAE animals. The in vitro treatment with 6b protected
oligodendrocyte cell line OLN-93 and neuronal cell line PC12
from mitogen-activated normal T cells or myelin basic protein-
activated encephalitogenic T cells. In conclusion, arylpiperazine
dopaminergic/serotonergic ligands suppress EAE through a
direct neuroprotective action and decrease inCNS inflammation.
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Biologically active compounds containing the arylpiperazine
scaffold are a class of privileged structures which, due to
their ability to act as dopamine and serotonine receptor
ligands, hold promise as antipshychotic, antidepressant, and
anxiolytic drugs (Lopez-Rodriguez et al. 1996; Taverne
et al. 1998; Gonzalez-Gomez et al. 2003; Zajdel et al.
2013). Interestingly, arylpiperazine dopaminergic ligands
are also endowed with neuroprotective ability. Aripiprazole,
a clinically approved arylpiperazine-based atypical antipsy-
chotic with partial dopaminergic/serotonergic agonist activ-
ity, has been shown to protect neurons from various toxic
insults, both in vitro and in vivo (Cosi et al. 2005; Eren et al.
2007; Matsuo et al. 2010; Koprivica et al. 2011). Moreover,
we have recently reported that in a series of 19 novel
arylpiperazine-based dopaminergic/serotonergic ligands
(Sukalovic et al. 2013), N-{4-[2-(4-phenyl-piperazin-1-yl)-
ethyl]-phenyl}-picolinamide (6a) and N-{3-[2-(4-phenyl-
piperazin-1-yl)-ethyl]-phenyl}-picolinamide (6b) were the
most potent in exerting an in vitro neuroprotective activity
against the free radical nitric oxide (NO) and neurotoxin 6-
hydroxydopamine (6-OHDA) (Tovilovic et al. 2012, 2013).
In addition, some arylpiperazine derivatives have displayed
an anti-inflammatory activity, reducing the inflammation in
carrageenan-induced hind paw edema model (Dundar et al.
2007), and inhibiting the production of proinflammatory
cytokines tumor necrosis factor (TNF) and IL-1b in bacterial
lipopolysaccharide-stimulated human leukocytes (Gouault
et al. 2004). Based on the above data, it is plausible to
assume that the combination of anti-inflammatory and
neuroprotective action of arylpiperazines could potentially
be useful in the treatment of inflammatory/autoimmune
damage of the central nervous system (CNS).
The experimental autoimmune encephalomyelitis (EAE) is
an animal model of brain inflammation with significant
clinical and pathological similarities to the human CNS
demyelinating diseases, including multiple sclerosis (MS)
and acute disseminated encephalomyelitis (ADEM) (Javed
and Khan 2014; Robinson et al. 2014). Following immuni-
zation with spinal cord homogenate or different myelin
antigens, susceptible animals, usually rodents, develop
lymphocyte infiltration of the CNS, an increase in blood-
brain barrier permeability, and demyelination, all of which
contribute to the flaccid paralysis as the most commonly
observed clinical feature of the disease (Robinson et al.
2014). Depending on the antigen used and the genetic
background, rodents can display a monophasic bout of EAE,
a relapsing-remitting form, or chronic EAE. While chronic
and relapsing-remitting forms of EAE may be more relevant
for studying MS (Robinson et al. 2014), an acute monopha-
sic EAE has been suggested to be far more similar to ADEM
than MS (Sriram and Steiner 2005). Although EAE might not
be a perfect mirror of human demyelinating diseases (Diem
et al. 2007), it has been considered useful in understanding
general immunological mechanisms and phenomena, as well
as in vivo interactions between the immune and the nervous
system (Farooqi et al. 2010). According to the generally
accepted concept of EAE pathogenesis, encephalitogenic
proteins prime and expand peripheral autoreactive CD4+ T
cells that migrate to the CNS and, upon reactivation by target
antigen, secrete proinflammatory cytokines, thus producing
inflammation and subsequent neurological signs (Kuerten
and Lehmann 2011; Rangachari and Kuchroo 2013). While
in some EAE models a demyelinating humoral immune
response is more pronounced (Diem et al. 2007), the major
culprits for causing neuroinflammation in EAE are interferon
(IFN)-c-producing T helper (TH)1 and, most notably,
interleukin (IL)-17-secreting TH17 cells (El-behi et al.
2010; Petermann and Korn 2011). Recently, the atypical
antipsychotic quetiapine, a dibenzodiazepine derivative con-
taining piperazine ring and acting as dopamine/serotonine
antagonist, has been found effective in reducing T-cell
activation and subsequent CNS demyelination in a mouse
model of EAE (Mei et al. 2012). However, the effect of
arylpiperazines dopaminergic/serotonergic ligands on CNS
inflammation/autoimmunity has not been explored so far.
In the present study, we investigated the potential thera-
peutic effect of arylpiperazines 6a and 6b in CNS inflam-
mation in a rat model of acute EAE. Our results demonstrate
that arylpiperazine treatment reduces CNS infiltration of
immune cells and ameliorates clinical signs of EAE, through
mechanisms possibly involving a direct protection of CNS
from the immune-mediated damage.
Materials and methods
EAE induction and monitoring
Female 8–10 week-old Dark Agouti rats were obtained from the
Institute for Medical Research, Military Medical Academy (Bel-
grade, Serbia). The rats were housed in the local animal facility
under conventional conditions with laboratory chow and water
ad libitum. The animals’ health status was monitored and any
infections were excluded according to Federation of European
Laboratory Animal Science Associations (FELASA) guidelines
(Nicklas et al. 2002). For EAE induction, the animals were
immunized by intradermal injection in the hind footpad of 100 lL
of emulsion made by a mixture of equal volumes of rat spinal cord
homogenate (SCH) in phosphate-buffered saline (PBS) (50% w/v)
and complete Freund’s adjuvant (CFA; Difco Laboratories, Detroit,
MI, USA). The rats were monitored daily for clinical signs of EAE,
and scored according to the following scale: 0, no clinical signs; 1,
flaccid tail; 2, hind limb paresis; 3, hind limb paralysis; 4, moribund
state or death (Badovinac et al. 1998). The following clinical
parameters were used: onset of EAE, the first day clinical signs were
observed; cumulative EAE score, the sum of all daily clinical scores;
and maximum EAE score, the highest clinical score observed during
disease. At the appropriate time-points (day 14, day 21, or day 28),
the rats were sacrificed by cervical dislocation and the tissues (spinal
cord, lymph nodes) were collected for further analysis. The study
was carried out in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC). All animal
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experiments were approved by the Local Ethics Committee for
Animal Experimentation (School of Medicine, University of
Belgrade), and all efforts were made to minimize animal suffering,
to reduce the number of animals used, and to utilize alternatives to
in vivo techniques, if available.
Treatment with arylpiperazines
Arylpiperazine compounds 6a and 6bwere synthesized as previously
described (Tovilovic et al. 2012). All arylpiperazines were stored at
+4°C as 10 mM stock solutions in dimethyl sulfoxide (DMSO;
Sigma-Aldrich, St. Louis, MO, USA), and were diluted in PBS
immediately before use. The animals were randomized into control
and treatment groups (≤ 3 rats per cage). The rats in the treatment
group were injected daily with arylpiperazines (10 mg/kg i.p.) in
three different settings: (i) starting on the day of immunization until
the end of the experiment (day 21 or 28), (ii) during first seven days,
and (iii) starting from the day 7 post-immunization until the end of
the experiment. Control animals were injected intraperitoneally with
PBS containing the appropriate amount of DMSO in PBS.
Isolation and flow cytometry analysis of mononuclear cells (MNC)
from spinal cord
Mononuclear cells (MNC) were isolated from the spinal cords of
immunized rats using a slight modification of the standard protocol
(Beeton and Chandy 2007). Spinal cords of animals perfused with
sterile PBS were dissociated through a wire mesh, and centrifuged at
700 g for 2 min. The pellets were then resuspended in 40% Percoll
(Sigma-Aldrich) and centrifuged on a discontinuous 40%/70%
Percoll gradient at 850 g for 25 min. The spinal cord MNC were
collected from the 40%/70% interface and washed two times (900 g
for 5 min) in Roswell Park Memorial Institute 1640 medium
(Sigma-Aldrich) supplemented with 2% rat serum. The purity of
MNC was > 95%, as determined by May-Gr€unwald-Giemsa
staining (not shown). Cells were counted and stained for the
presence of CD3, CD8, CD11b (BD Biosciences, San Jose, CA,
USA), and CD4 (BioLegend, San Diego, CA, USA), and concom-
itantly for the intracellular content of IFN-c (BioLegend), IL-17
(eBioscience, San Diego, CA, USA), and IL-10 (BD Biosciences)
by using the fixation/permeabilization kit and anti-rat monoclonal
antibodies conjugated with fluorescein isothiocyanate (FITC),
phycoerythrin (PE), peridinin chlorophyll protein (PercP), allophyc-
ocyanin (APc), V450, PECy7 and AlexaFluor 647, following the
manufacturer’s instructions. Intracellular staining was performed
after a 4-h stimulation with phorbolmyristate acetate (100 ng/mL)
and ionomycin (400 ng/mL) in the presence of brefeldin A (5 lM)
(all from Sigma-Aldrich). The stained cells were counted using a
FACSAria III flow cytometer (BD Biosciences), and the results were
analyzed with the FlowJo software (LLC, Ashland, OR, USA).
Real-time RT-PCR
Total RNA was extracted using TRIZOL and 1 lg of RNA was
reversely transcribed with M-MuLV reverse transcriptase and
random hexamers (all from Life Technologies, Carlsbad, CA,
USA). The real-time PCR analysis was performed in a Realplex
Mastercycler (Eppendorf, Hamburg, Germany), using TaqMan
Master Mix and the following TaqMan primers and probes (Life
Technologies): IL-1 (Rn00580432_m1), IL-12p35 (Rn005845
38_m1), IL-23p19 (Rn00590334_g1), IL-6 (Rn01410330_m1),
IL-17A (Rn01757168_m1), transforming growth factor (TGF)-b1
(Rn00572010_m1), IFN-c (Rn00594078_m1), TNF (Rn999990
17_m1), IL-1 receptor antagonist (IL-1Ra) (Rn02586400_m1),
granulocyte-macrophage colony-stimulating factor (GMCSF)
(Rn01456850_m1), IL-10 (Rn 00563409_m1), T-bet (Rn01461633_
m1), RORct (Rn01533717_g1), and Foxp3 (Rn01525092_m1). The
geometric mean of threshold cycle (Ct) values of housekeeping
genes (18s ribosomal RNA) was subtracted from the Ct values of
target genes to obtain DCt, and the relative gene expression was
determined as 2DCt.
Immunoblotting
Tissues were lysed in lysis buffer (30 mMTris-HCl, pH 8.0, 150 mM
NaCl, 1% NP-40) containing 1 mM phenylmethylsulfonyl fluoride,
1 mM Na-orthovanadate, 10 mM NaF, and protease inhibitor
cocktail (all from Sigma-Aldrich) on ice for 30 min, centrifuged at
14 000 g for 15 min at +4°C, and the supernatants were collected.
Equal amounts of protein from each sample were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA,
USA). Following incubation with primary rabbit antibodies against
poly (ADP ribose) polymerase (PARP), phospho-Akt (Ser473),
phospho-p70S6 kinase 1 (p70S6K; Thr389), phospho-mammalian
target of rapamycin (mTOR; Ser2448), or actin (Cell Signaling
Technology, Cambridge, MA, USA), and peroxidase-conjugated
goat anti-rabbit IgG (Southern Biotech, Birmingham, AL, USA) as
the secondary antibody, specific protein bands were visualized using
the enhanced chemiluminescence reagent (GE Healthcare, Pollards
Wood, UK). The results were quantified by densitometry using
ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Histological examination of MNC infiltration and apoptosis
Surgically removed specimens of rat spinal cords were fixed in 4%
paraformaldehyde and embedded in paraffin. Tissue sections (5 lm
thick) were deparaffinized in xylol, dehydrated in increasing alcohol
concentrations, and stained with hematoxylin–eosin (HE). Digital
images of HE sections were made on a Leica DM4000B LED (Leica
Microsystems, Wetzlar, Germany) microscope equipped with a
Digital Camera (Leica DFC295) and LAS 4.4 Software. Morpho-
metric analysis of areas with mononuclear cell infiltrate was done in
Fiji (ImageJ 1.49b) using ‘analyze measurements’ tool.
DNA fragmentation assay for apoptosis detection
To identify fragmented DNA as a marker of apoptotic cell death, a
TdT-mediated dUTP nick-end labeling (TUNEL) assay was
performed on paraformaldehyde-fixed, paraffin-embedded lumbar
spinal cord sections. After deparaffinization and permeabilization
with 0.2% Triton X-100, cells were treated with 3% bovine serum
albumin and with TUNEL reaction mixture (Roche, Mannheim,
Germany). Then the converter for alkaline phosphatase was applied,
and Fast red (both from Roche) was used to visualize the signal for
light microscopy. Apoptotic cells, displaying granular red nuclear
staining were counted in five random medium-power fields (9 200)
at each cell slide.
Co-cultivation experiments
Rat oligodendrocyte cell line OLN-93 (Richter-Landsberg and
Heinrich 1996) was a kind gift from Marcus Kipp (Institute of
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Neuroanatomy, Faculty of Medicine, Aachen, Germany). Cells were
maintained in Dulbecco’s modified eagle medium containing 5%
fetal calf serum and 1% penicillin/streptomycin (all from Sigma-
Aldrich). Rat pheochromocytoma PC12 cell line was obtained from
the European Collection of Cell Cultures (Salisbury, UK) and grown
in high glucose Dulbecco’s modified eagle medium containing 10%
horse serum (Sigma-Aldrich), 5% FetalClone III serum (Thermo
Fisher Scientific, Waltham, MA, USA) and 1% penicillin/strepto-
mycin. Single cell suspensions of lymphocytes were obtained from
the cervical lymph nodes of non-immunized or draining lymph
nodes of SCH-immunized rats. OLN-93 or PC12 cells were
incubated with lymphocytes in Corning Transwell 3460 system
(Corning Inc. Life Sciences, Tewksbury, MA, USA). OLN-93 and
PC12 cells were incubated in 12-well plate (3 9 105 cells/well),
while lymphocytes (1 9 106) were seeded in permeable inserts with
0.4 lM pores. The cells were incubated with 10 lM of arylpiper-
azines for 1 h, followed by stimulation with T-cell mitogen
Concanavalin A (Con A; 5 lg/mL) or guinea pig myelin basic
protein (MBP; 10 lg/mL) (both from Sigma-Aldrich) for 48 or
72 h, respectively. The concentration of arylpiperazines (10 lM)
was chosen based on a previous study in which it did not exert any
toxic effects on human SH-SY5Y neuronal cell line (Tovilovic et al.
2012). Control cells were incubated with the appropriate amount of
solvent (DMSO).
Determination of cell viability
At the end of the co-cultivation, the cell culture inserts were
removed and the viability of OLN-93 and PC12 cells was
determined by colorimetric assessment (570 nm) of mitochondrial
dehydrogenase-mediated conversion of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) to purple formazan, as
previously described (Mijatovic et al. 2004). The results are
presented as % viability of the untreated control, which was set to
100%.
Statistical analysis
The differences in EAE clinical score were analyzed by mixed
ANOVA with repeated measures, followed by Dunnett’s test for
multiple comparisons. In other experiments, Student’s t-test or one-
way ANOVA followed by Tukey’s test was used to assess the
differences between two or more independent groups, respectively.
The data were presented as mean  SEM values. A p value of
< 0.05 was considered significant.
Results
Arylpiperazine treatment reduces clinical signs of EAE
The chemical structures of arylpiperazines 6a and 6b are
presented in Fig. 1. Both compounds were first tested in non-
immunized animals for the signs of acute toxicity (respiratory
distress, impaired body weight gain, anorexia, weakness,
apathy, and death), as well as for the effects that could
interfere with the monitoring of EAE clinical signs (rigidity,
sedation, and change of the tail tonus). The doses over
20 mg/kg induced abdominal writhing in some of the rats, so
the dose of 10 mg/kg, which did not cause any obvious side
effects, was chosen for further experiments. SCH/CFA-
immunized animals developed classical monophasic acute
disease with the symptom-free inductive phase (day 0–7
post-immunization) and the effector phase (from day 8
onwards, with the disease peak approx. at day 14), followed
by recovery phase. The rats were treated with arylpiperazines
daily from the day of EAE induction until the end of the
experiment (day 28). As presented in Fig. 2a, both treatments
significantly reduced the EAE clinical score at several time-
points. The analysis of the body mass change demonstrated
that arylpiperazine treatment prevented the disease-associ-
ated weight loss, thus further confirming its protective effect
(Fig. 2b). An additional analysis revealed that the mean
cumulative clinical score was significantly lower in arylpip-
erazine-treated rats compared to EAE controls (Table 1). The
mean maximum score was also reduced by arylpiperazines,
but the difference was statistically significant only for 6b
(Table 1.) Similarly, the disease onset was significantly
delayed in rats treated with 6b, while the difference was not
significant for the treatment with 6a (Table 1). Because of
the better efficiency, 6b was selected for the further study.
Since the clinical score did not significantly change from day
22–28, the experiment duration was reduced to 21 day to
minimize animal suffering.
Arypiperazine treatment exerts protection during the
effector, but not inductive phase of EAE
To get some insight into the mechanisms of the observed
protection in EAE, we administered 6b during the inductive
(day 0–7) or effector phase (from day 8 onwards) of the
disease. In contrast to the continuous treatment (Fig. 2a), no
protection was observed in rats treated with 6b during the
inductive phase of EAE (Fig. 2c). On the other hand, animals
that received 6b during the effector phase of EAE developed
a significantly milder disease (Fig. 2d), as reflected by a
significantly later mean onset (12.3  0.3 vs. 11.3  0.3),
and lower mean cumulative score (8.4  1.1 vs. 13.4  1.2)
and mean maximum score (1.3  0.2 vs. 2.0  0.2),
compared to control EAE rats (p < 0.05). The observed
Fig. 1 Chemical structures of arylpiperazines 6a and 6b.
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protection during the effector, but not inductive phase of the
disease indicates that arylpiperazines might interfere directly
with the immune-mediated CNS damage, rather than activa-
tion/expansion of autoimmune cells at the periphery.
Consistent with the delayed onset, the disease in arylpiper-
azine group reached its peak later than in control animals
(day 15–16 vs. day 13–14, respectively; Fig. 2a, c and d).
Nevertheless, we decided to perform further mechanistic
analyses at the same time-point (day 14 post-immunization)
in order for them to reflect not only the overall reduction, but
also the delayed onset/progression of clinical signs.
Table 1 The effect of arylpiperazines on EAE clinical features
Cumulative
clinical score
Maximum clinical
score
Day of
onset
Control 19.3  2.0 2.1  0.4 10.5  0.2
6a 11.2  2.0* 1.2  0.4 11.8  1.0
6b 9.5  2.0* 0.8  0.1* 12.7  1.0*
The SCH-CFA-immunized rats were treated daily with PBS/DMSO
(control; n = 8) or arylpiperazines 6a or 6b (10 mg/kg; n = 8 per group)
for 28 days. The disease was monitored and the clinical parameters
were calculated (*p < 0.05).
(a) (b)
(c) (d)
Fig. 2 Arylpiperazines reduce clinical signs of experimental autoim-
mune encephalomyelitis (EAE) by acting at the effector phase of the
disease. (a and b) The rats were treated daily with phosphate-buffered
saline (PBS)/DMSO (control; n = 8) or arylpiperazines (10 mg/kg;
n = 8 per group) from the day of spinal cord homogenate (SCH)-
complete Freund’s adjuvant (CFA) immunization (day 0) until the end
of experiment (day 28). The clinical signs (a) and body mass change
(b) were monitored at the indicated time-points (#p < 0.05 and
*p < 0.05 vs. 6a and 6b treatment, respectively). (c and d) The rats
immunized with SCH-CFA were treated daily with arylpiperazines
(10 mg/kg) from the day 0–7 (c) or day 8–21 (d), and the clinical signs
of the disease were recorded (n = 8 rats per group; *p < 0.05 vs. 6b
treatment).
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Arylpiperazine treatment reduces CNS infiltration of
immune cells in EAE
We next assessed the influence of arylpiperazine treatment
on the size of immune cell infiltrates in the CNS of diseased
animals. The microscopic analysis of HE-stained lumbar
spinal cord sections, performed at day 14 post-immuniza-
tion, revealed an extensive subpial/perivascular cellular
infiltration in control animals with EAE (Fig. 3a). Inflam-
matory cells were also present in the spinal cord anterior
horns and in the spinal cord white matter, while the analysis
at higher magnification demonstrated that the infiltrates
mainly consisted of MNC with sporadic neutrophils
(Fig. 3a). On the other hand, perivascular cellular infiltrates,
as well as those observed in the superficial parts of the white
matter at day 14 of EAE induction, were clearly more
discrete in rats treated with 6b (Fig. 3a). Accordingly, the
morphometric analysis demonstrated that the spinal cord
area containing infiltrated cells was reduced in arylpiper-
azine-treated animals (Fig. 3b). To further confirm arylpip-
erazine-mediated reduction in the size of CNS immune
infiltrates, animals were sacrificed at day 14 post-immuni-
zation, and MNC obtained by spinal cord perfusion were
counted. In accordance with the histochemistry data, there
was a significant reduction in the number of CNS-infiltrating
MNC observed in 6b-treated rats compared to the control
group (Fig. 3c). On the other hand, there was no significant
(a)
(b) (c) (d)
Fig. 3 Arylpiperazine treatment reduces CNS immune infiltration in
experimental autoimmune encephalomyelitis (EAE). (a and b) At day
14 post-immunization, the spinal cord lumbar sections were analyzed
by immunocytochemistry for the presence of immune cell infiltrates in
spinal cord homogenate (SCH)-complete Freund’s adjuvant (CFA)-
immunized control (n = 5) and 6b-treated rats (10 mg/kg/day; n = 5).
The representative micrographs are shown in (a), while the results of
the morphometric analysis are presented in (b) (*p < 0.05). (c and d)
mononuclear cells (MNC) counts in the spinal cord perfusates (c) or
draining (popliteal) lymph nodes (d) obtained from SCH-CFA-immu-
nized control (n = 5) and 6b-treated rats (10 mg/kg/day; n = 5) are
presented (*p < 0.05).
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change in the MNC number in the draining (popliteal)
lymph nodes of 6b-injected animals (Fig. 3d). The observed
decrease in CNS immune infiltration is consistent with the
delayed and reduced neurological symptomatology in aryl-
piperazine-treated EAE rats.
Arylpiperazine treatment reduces the expression of
inflammatory mediators in the CNS tissue, but not CNS-
infiltrated MNC in EAE
We next investigated how the arylpiperazine-mediated
reduction in CNS immune infiltration in EAE correlates
with the expression of inflammatory mediators/regulators in
the CNS tissue. To that aim we analyzed the spinal cord
levels of mRNA for the proinflammatory cytokines TNF, IL-
6, IL-1, and GMCSF, TH1 cytokines IL-12 and IFN-c, TH17
cytokines IL-23 and IL-17, anti-inflammatory/immunosup-
pressive mediators IL-10, TGF-b, and IL-1Ra, as well as
signature transcription factors of TH1 (T-bet), TH17 (RORct),
and regulatory T cells (Foxp3). The real-time RT-PCR
analysis revealed that the mRNA expression of all mediators,
except IL-12 and IL-23, was significantly increased at day 14
in the spinal cords of rats with EAE, compared to non-
immunized animals (data not shown). In accordance with the
reduction of the disease severity in the same experiment
(Fig. 4a), the treatment with 6b significantly decreased the
CNS levels of all investigated mRNAs, except those for IL-
12 and IL-23 (Fig. 4b–d). In contrast to the results obtained
with the whole spinal cord tissue containing the infiltrated
MNC, no significant differences were observed between
control and 6b-treated animals when mRNA levels of
proinflammatory/anti-inflammatory mediators were com-
pared in MNC isolated from the spinal cord (Fig. 4e).
Accordingly, the treatment with 6b did not significantly alter
the composition of MNC infiltrates obtained from the CNS at
day 14 post-immunization. Namely, the flow cytometry
analysis revealed that the frequencies of CD3+CD4+ T cells,
CD3+CD8+ T cells, CD4+ cells producing IFN-c, IL-10, or
IL-17, or CD8+ cells producing IFN-c or IL-10, did not
significantly differ in spinal cord MNC infiltrates of control,
compared to 6b-treated rats (Fig. 5). Therefore, the observed
decrease in the expression of proinflammatory/anti-inflam-
matory mediators in the CNS of arylpiperazine-treated
animals is due to a delay and decrease in MNC infiltration,
rather than specific changes in gene expression or cellular
composition of the infiltrates.
Arylpiperazine treatment reduces apoptosis and increases
the activity of Akt/S6K signaling pathway in the CNS of EAE
rats
To evaluate the effect of arylpiperazine treatment on the
apoptotic death of CNS cells during EAE, we performed
TUNEL assay for DNA fragmentation. While no apoptotic
cells were observed in the spinal cord of healthy animals at
day 14 post-immunization, the TUNEL-positive nuclei were
found in cells located in the white mater of spinal cord
samples from EAE animals (Fig. 6a). According to their
position and size, the apoptotic cells were mostly glial cells,
presumably oligodendrocytes. Consistent with the protective
effect of arylpiperazines, TUNEL-positive cellular nuclei
were significantly less frequent in the spinal cord sections
from 6b-treated EAE animals (Fig. 6a). The arylpiperazine-
mediated reduction of apoptotic DNA damage was further
confirmed by a decrease in PARP cleavage (Fig. 6b), which
facilitates apoptotic demise by blocking the DNA-repairing
activity of PARP, and serves as a marker of cells undergoing
apoptosis (Oliver et al. 1998). We also examined the ability
of arylpiperazine treatment to modulate phosphorylation of
the anti-apoptotic kinase Akt and its downstream effectors
mTOR and p70S6K in the CNS of rats with EAE. The
immunoblot analysis of spinal cord homogenates demon-
strated that 6b-treated rats, compared to control EAE
animals, displayed an increased phosphorylation of Akt
and p70S6K at day 14 post-immunization, while the
phosphorylation of mTOR was not significantly affected
(Fig. 6). These data indicate that the activation of anti-
apoptotic Akt/p70S6K signaling might contribute to the
delayed onset/progression and overall suppression of EAE in
arylpiperazine-treated animals.
Arylpiperazine treatment protects oligodendrocyte- and
neuron-like cell lines from T-cell-dependent damage
in vitro
As we have previously shown that arylpiperazine treatment
exerts an in vitro neuroprotective activity against neurotoxins
6-OHDA and NO (Tovilovic et al. 2012, 2013), we exam-
ined if it can antagonize immune-mediated damage of
oligodendrocytes and neurons. To address this issue, we
employed a co-cultivation system in which rat oligodendro-
cyte cell line OLN-93 and rat PC12 neuron-like cell line were
incubated with rat lymph node MNC stimulated with T-cell
mitogen Con A or auto-antigen MBP. Both Con A-activated
normal MNC and MBP-stimulated MNC from SCH/CFA-
immunized rats markedly reduced the viability of OLN-93
and PC12 cells, as demonstrated by MTT assay (Fig. 7a–d).
The treatment with 6b significantly protected both cell lines
from the damage induced by activated MNC (Fig. 7a–d),
without affecting MNC expression of proinflammatory or
anti-inflammatory mediators (Fig. 7e). Therefore, arylpiper-
azine treatment can directly protect oligodendrocytes and
neurons from immune-mediated damage without exerting
immunomodulatory activity.
Discussion
The present study for the first time demonstrates the ability of
novel arylpiperazine derivatives to ameliorate immune-
mediated CNS damage, delaying the onset/progression and
reducing the maximal disease score in a rat model of EAE.
© 2015 International Society for Neurochemistry, J. Neurochem. (2015) 135, 125--138
Arylpiperazine D2/5-HT1A ligands suppress EAE 131
(a) (b)
(c)
(e)
(d)
Fig. 4 Arylpiperazine treatment reduces the expression of mRNA for
the inflammatory mediators in the CNS tissue, but not CNS-infiltrated
mononuclear cells (MNC). (a–e) The rats were immunized with spinal
cord homogenate (SCH)-complete Freund’s adjuvant (CFA), receiving
phosphate-buffered saline (PBS)/DMSO (control, n = 8) or 6b
(10 mg/kg/day, n = 8). The clinical signs were monitored until day
14 (a), when RNA was isolated for the RT-PCR determination of
proinflammatory/anti-inflammatory mediators and transcription factors
in the spinal cord lumbar sections (b–d) or CNS-infiltrated MNC (e)
(*p < 0.05). The results are presented relative to the values obtained
in untreated (b–d) or control experimental autoimmune encephalo-
myelitis (EAE) animals (e).
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The protective effect was mediated by the reduction in CNS
immune infiltration in the absence of any overt immunosup-
pressive/immunomodulatory action.
The protective effect in EAE of quetiapine, a dib-
enzodiazepine derivative with the piperazine ring, was
apparently mediated through inhibiting the proliferation of
autoimmune T cells (Mei et al. 2012). However, there is a
line of evidence arguing against direct immunomodulatory
action of arylpiperazines in our experiments. Firstly, the
absence of the protective effect in the inductive phase
indicates the inability of the drugs to interfere with the
activation and/or expansion of the encephalitogenic cells at
the periphery. Secondly, the results of the RT-PCR analysis
of CNS-infiltrated or in vitro stimulated MNC confirm that
arylpiperazines failed to affect the expression of crucial
transcription factors and cytokines (TNF, IL-1, GMCSF,
IFN-c, IL-17) involved in CNS inflammation. Thirdly, the
flow cytometry analysis of major encephalitogenic/regulatory
immune cell populations clearly suggests that arylpiperazines
did not act by altering the cellular composition of the
inflammatory CNS infiltrates. Taken together, these data
indicate that the protective effect of arylpiperazine deriva-
tives was not due to a direct interference with peripheral
activation/expansion, or target tissue reactivation of enceph-
alitogenic TH1 and TH17 cells.
The most likely mechanism underlying the beneficial
action of arylpiperazines in EAE is the non-selective
reduction of immune cell infiltration into the CNS, affecting
both encephalitogenic TH1 and TH17 cells, as well as those
producing proinflammatory cytokines TNF, IL-6, GMCSF,
and IL-1, or immunoregulatory/immunosuppressive IL-10,
TGF-b, and IL-1Ra. Since the analysis of CNS infiltration
(a)
(b)
Fig. 5 Arylpiperazine treatment does not affect cellular composition of
mononuclear cells (MNC) infiltrates and their cytokine production. (a
and b) At day 14 post-immunization, the presence of various MNC
subpopulations was quantified by flow cytometry in spinal cord
infiltrates from spinal cord homogenate (SCH)-complete Freund’s
adjuvant (CFA)-immunized control and 6b-treated rats (10 mg/kg/day;
n = 8 per group; *p < 0.05). The representative dot plots are shown in
(b).
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and cytokine expression in both control and arylpiperazine-
treated group was performed at the same time-point, the
observed differences presumably reflected not only the
overall reduction, but also delayed onset/progression of
neurological symptoms. As the arylpiperazine treatment was
unable to affect the disease in the inductive phase or alter the
expression of various inflammation-related molecules in the
infiltrated cells, it seems plausible that the protective action
was actually exerted in the target tissue rather than infiltrating
cells themselves. For example, the possibility that arylpip-
erazines could affect the adhesion properties of CNS vascular
endothelial cells and/or chemokine/proinflammatory cyto-
kine production by CNS resident cells seems worthy of
investigation. In addition, the observed anti-apoptotic action
of arylpiperazines in the CNS of EAE animals, as well as our
in vitro data, suggest that the direct protection of oligoden-
drocytes and neurons from immune-mediated damage might
contribute to the reduced neuroinflammation. Namely, both
oligodendrocyte and neuronal death have been observed in
CNS during MS/EAE (Das et al. 2008a,b; Guyton et al.
2010; Herz et al. 2010; Fang et al. 2013), and the damage-
associated molecular patterns released from injured CNS
cells (heat shock proteins, adenine nucleotides, high-mobility
group box 1, uric acid, and RNA), or formed in the
extracellular matrix (hyaluronan fragments, tenascins, fibro-
nectin, and sulfated proteoglycans), can perpetuate CNS
inflammation (Miranda-Hernandez and Baxter 2013; Gaudet
and Popovich 2014; Kigerl et al. 2014). It is therefore
conceivable that the direct protection of oligodendrocytes
and neurons by arylpiperazines, in addition to its immediate
beneficial effect, contributed to a decrease in CNS inflam-
mation by reducing the release of proinflammatory damage-
associated molecular patterns.
There is a question of the molecular mechanism(s)
underlying the arylpiperazine-mediated direct protection of
CNS cells from the damage incurred by activated immune
cells. We have recently reported that the activation of the
prosurvival kinase Akt was responsible for arylpiperazine-
mediated protection of SH-SY5Y cells exposed to a neuro-
toxic free radical NO (Tovilovic et al. 2012). Akt can block
FOXO/p53-dependent transcription of ‘death’ genes,
increase NF-jB-mediated transcription of survival genes,
and directly inactivate pro-apoptotic Bcl-2 family members
such as Bcl-2-associated death promoter (Brunet et al. 2001;
(a)
(b)
Fig. 6 Arylpiperazine treatment reduces
apoptosis and increases Akt/p70S6K
activity in the CNS of experimental
autoimmune encephalomyelitis (EAE) rats.
(a) Apoptotic nuclei (arrows) were detected
by TdT-mediated dUTP nick-end labeling
(TUNEL) staining in the spinal cord sections
of healthy (n = 3), spinal cord homogenate
(SCH)-complete Freund’s adjuvant (CFA)-
immunized control (n = 5), and 6b-treated
rats (10 mg/kg/day; n = 5) at day 14
post-immunization. The representative
micrographs and the percentages of
apoptotic cells are shown (*p < 0.05). (b)
The cleavage of PARP and activation status
(phosphorylation) of Akt, p70S6K, and
mTOR at day 14 post-immunization were
examined by immunoblotting in the lumbar
spinal cord tissue fromSCH-CFA-immunized
control (n = 4) and 6b-treated rats (10 mg/
kg/day; n = 4). The densitometry data are
presented relative to actin signals
(*p < 0.05).
© 2015 International Society for Neurochemistry, J. Neurochem. (2015) 135, 125--138
134 M. Popovic et al.
Diem et al. 2007), while its downstream effector p70S6K
maintains transcription and translation at the levels required
for neuronal survival under apoptotic stress (Wu et al. 2004;
Chen et al. 2010). In the present study, arylpiperazine
treatment increased the phosphorylation of both Akt and
p70S6K in the CNS of EAE rats. This is consistent with the
recent finding that the engagement of estrogen receptor b on
oligodendrocytes promoted remyelination in EAE through
activation of Akt/p70S6K signaling (Khalaj et al. 2013;
Kumar et al. 2013), and suggests that the activation of Akt
and p70S6K in the CNS at least partly contributed to the
beneficial effect of arylpiperazines in EAE. It should be
noted that mTOR, the kinase that phosphorylates p70S6K
upon activation by Akt (Magnuson et al. 2012), is required
for the development of encephalitogenic TH1 and TH17 cells
(Delgoffe et al. 2011). Accordingly, pharmacological inhi-
bition of mTOR/S6K signaling with rapamycin suppress
EAE by modulating both effector and regulatory T-cell
function (Donia et al. 2009; Esposito et al. 2010). Therefore,
it appears that mTOR/S6K axis might play a double role in
neuroinflammation, promoting oligodendrocyte and neuronal
survival on the one hand, while driving the pathogenic T-cell
(a) (b)
(c) (d)
(e)
Fig. 7 Arylpiperazines protect
oligodendrocyte and neuronal cell lines
from T cell-dependent damage in vitro,
without exerting immunomodulatory
activity. (a–d) Rat oligodendrocyte cell line
OLN-93 (a and b) and rat neuron-like cell
line PC12 (c and d) were incubated with
normal lymph node mononuclear cells
(MNC) stimulated with T-cell mitogen Con
A (5 lg/mL) (a and c), or draining lymph
node from spinal cord homogenate (SCH)-
complete Freund’s adjuvant (CFA)-
immunized rats, stimulated with CNS
antigen myelin basic protein (MBP) (10 lg/
mL) (b and d), in the presence or absence of
6b (20 lM). The viability of OLN-93 and
PC12 cells was determined by MTT assay,
and the results of triplicate measurements
from a representative of three experiments
are presented (*p < 0.05 vs. control cells;
#p < 0.05 vs. corresponding treatment
without 6b). (e) Lymph node MNC
(5 x 106) from healthy or SCH-CFA-
immunized rats (n = 5 per group) were
stimulated with Con A (5 lg/mL) or MBP
(10 lg/mL), respectively, and RNA was
isolated for the RT-PCR determination of
proinflammatory/anti-inflammatory
mediators and transcription factors. The
results are presented relative to the values
obtained in cells treated with Con A or MBP
alone.
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responses on the other hand (Dello et al. 2013). Since
arylpiperazine treatment in our study markedly reduced
MNC infiltration, it is likely that CNS cells, rather than
infiltrated T cells, were the source of the increased Akt/
p70S6K activity in the CNS tissue. Interestingly, the
activation of mTOR was not increased by arylpiperazine
treatment, which could be explained by the ability of Akt to
phosphorylate p70S6K independently of mTOR (Jaeschke
et al. 2002), and/or by the involvement of other intracellular
signaling pathways able to activate p70S6K independently of
Akt/mTOR axis (Fang et al. 2007; Deguil et al. 2008; Liu
et al. 2013). Nevertheless, arylpiperazine-mediated modula-
tion of Akt/mTOR/p70S6K signaling in various types of
CNS and immune cells, as well as its role in arylpiperazine
protection from neuroinflammation, remain to be investi-
gated in more detail.
Finally, it should be noted that the arylpiperazines
investigated in the present study act as D2 and 5-HT1A
receptor ligands (Sukalovic et al. 2013), displaying partial
D2 agonist activity (Tovilovic et al., unpublished results). In
the present study, a somewhat better efficiency of 6b,
reflected in the later onset and lower maximal disease score
(Table 1), correlated with its higher binding affinities for D2
(Ki 1400 and 71.6 nM for 6a and 6b, respectively) and 5-
HT1A receptors (Ki 304.9 and 2.4 nM) (Sukalovic et al.
2013). Therefore, it is possible that dopamine/serotonine
receptor binding in arylpiperazine-mediated beneficial effects
in neuroinflammation. This is consistent with the findings
that D2 partial agonist bromocriptine and the interference
with serotonergic activity reduce CNS inflammation and
clinical severity of EAE (Dijkstra et al. 1994; Freire-Garabal
et al. 2003; Yuan et al. 2012), while D2 antagonism
exacerbates the disease (Nakano et al. 2008). On the other
hand, the in vitro neuroprotective action of some dopami-
nergic ligands, including the arylipiperazines investigated
here, was apparently independent of dopamine receptor
binding (Ramirez et al. 2003; Gu et al. 2004; Matsuo et al.
2010; Tovilovic et al. 2012, 2013). Nevertheless, since
dopaminergic dysfunction could contribute to anxiety and
depression found both in EAE and MS (Feinstein 2007;
Gentile et al. 2015), arylpiperazine-mediated interaction with
dopaminergic/serotonergic signaling, even if not directly
involved in the prevention of neuroinflammatory damage,
might help alleviate the accompanying mood disturbances. It
remains on future studies to clarify the exact role of different
types of dopamine/serotonine receptors in the neuroprotec-
tive and behavioral effects of arylpiperazines in neuroin-
flammation.
In conclusion, our results indicate that arylpiperazine
dopaminergic/serotonergic ligands suppress EAE through
mechanisms involving Akt/p70S6K-mediated neuroprotec-
tion and subsequent decrease in CNS immune infiltration,
rather than direct immunomodulatory action. These data
support further exploration of arylpiperazine compounds as
possible adjuncts to immune-targeted therapy of ADEM,
MS, and other neuroinflammatory disorders.
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